
London-based biotech startup Big Picture Bio has come out of stealth with a total of €2.55 million (£2.2 million) in funding. The company uses AI to design combination treatments for cancer and other complex diseases.
The funding includes a €1.75 million (£1.5 million) pre-Seed round, which was co-led by Kadmos Capital and Exceptional Ventures.
Big Picture Bio also received €815,000 (£700,000) in non-dilutive funding through Innovate UK’s Investor Partnerships Programme. Gloucester Ventures and angel investor John White also joined the pre-Seed round.
“I had the privilege of working closely with Kerstin and Mark at the very beginning of Deep Science Ventures, and saw first-hand the determination, conviction and sheer resolve they bring to building ambitious, scalable businesses,” said Remy Kesrouani, Managing Partner, Kadmos Capital.
He added, “Big Picture Bio is the culmination of that journey, applying a genuinely differentiated approach to AI to one of drug development’s hardest problems: predicting how complex clinical trials will actually behave.”
Big Picture Bio was founded by CEO Dr. Kerstin Papenfuss and CTO Dr. Mark Hammond. The company has developed a generative AI “world model” that simulates how tumours, immune cells, and surrounding tissues interact.
The technology is designed to help researchers identify which drug combinations could work best against cancer. It also aims to find the right order in which different treatments should be given to help slow or prevent cancer from developing resistance.
Before starting Big Picture Bio, both founders spent several years at Deep Science Ventures. Papenfuss led its therapeutics team and helped launch 12 companies focused on treatments and related technologies. She previously worked at LifeArc and the Cell and Gene Therapy Catapult.
“Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones,” said Dr Kerstin Papenfuss, CEO and co-founder, Big Picture Bio.
She added, “That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab.”
Big Picture Bio will use the new funding to move its AI-designed cancer treatment combinations from computer models into laboratory testing. The company will initially focus on cancer and diseases linked to the immune system.
In the longer term, Big Picture Bio wants to reduce the need for trial-and-error when testing drug combinations. Its goal is to eventually use AI to design completely new treatments from the ground up, instead of only combining existing drugs.